Join
Live feed
·
PRReleasevia Quantisnow
Rallybio Corporation logo
Recursion Pharmaceuticals Inc. logo

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

ByQuantisnow·Wall Street's wire, on your screen.
RLYB· Rallybio CorporationRXRX· Recursion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLYB (Rallybio Corporation), RXRX (Recursion Pharmaceuticals Inc.) and more on Quantisnow.